Log In
Print this Print this

CAR-T CD19, CBM-C19.1

  Manage Alerts
Collapse Summary General Information
Company Cellular Biomedicine Group Inc.
DescriptionT cells expressing a chimeric antigen receptor (CAR) specific to the CD19 antigen
Molecular Target CD19
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase I
Standard IndicationLeukemia
Indication DetailsTreat B cell acute lymphocytic leukemia (ALL); Treat CD19-positive B cell acute lymphocytic leukemia (ALL)
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today